Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1471-0528.1972.tb15756.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
From Theory to Practice: Bone Health in Women with Early Breast Cancer Treated with Aromatase Inhibitors.
Curr Oncol
February 2021
Department of Medical Oncology, Hospital de São Francisco Xavier, Centro Hospitalar de Lisboa Ocidental, 1449-005 Lisbon, Portugal.
Aromatase inhibitors (AI) are extensively used as adjuvant endocrine therapy in post-menopausal women with hormone receptor-positive early breast cancer (HR+ EBC), but their impact on bone health is not negligible. This work aimed to assess bone loss, fracture incidence, and risk factors associated with these events, as well as the prognostic influence of fractures. We have conducted a retrospective cohort study of women with HR+ EBC under adjuvant therapy with AI, during a 3-year period.
View Article and Find Full Text PDFPrimary uterine ectomesenchymoma harboring a DICER1 mutation: case report with molecular analysis.
Virchows Arch
August 2021
Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, Montebello, N-0310, Oslo, Norway.
Ectomesenchymoma is an exceedingly rare biphasic malignant tumor characterized by the presence of mesenchymal and neuroectodermal elements. The majority of patients are infants or children. We describe the first case of this entity diagnosed as a primary uterine tumor.
View Article and Find Full Text PDF50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened?
Endocr Relat Cancer
January 2021
Dallas/Ft. Worth Living Legend Chair of Cancer Research, Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Following the discovery and approval of the oral contraceptive, the pharmaceutical industry sought new opportunities for the regulation of reproduction. The discovery of the first non-steroidal anti-oestrogen MER25, with antifertility properties in laboratory animals, started a search for 'morning-after pills'. There were multiple options in the 1960s, however, one compound ICI 46,474 was investigated, but found to induce ovulation in subfertile women.
View Article and Find Full Text PDFCold Atmospheric Pressure Plasma (CAP) as a New Tool for the Management of Vulva Cancer and Vulvar Premalignant Lesions in Gynaecological Oncology.
Int J Mol Sci
October 2020
Predictive, Preventive Personalised (3P) Medicine, Department of Radiation Oncology, Rheinische Friedrich-Wilhelms-Universität Bonn, 53105 Bonn, Germany.
Vulvar cancer (VC) is a specific form of malignancy accounting for 5-6% of all gynaecologic malignancies. Although VC occurs most commonly in women after 60 years of age, disease incidence has risen progressively in premenopausal women in recent decades. VC demonstrates particular features requiring well-adapted therapeutic approaches to avoid potential treatment-related complications.
View Article and Find Full Text PDFPersistence of Late Substantial Patient-Reported Symptoms (LAPERS) After Radiochemotherapy Including Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: A Report From the EMBRACE Study.
Int J Radiat Oncol Biol Phys
January 2021
Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna/General Hospital of Vienna, Vienna, Austria.
Purpose: This report describes the persistence of late substantial treatment-related patient-reported symptoms (LAPERS) in the multi-institutional EMBRACE study on magnetic resonance image guided adaptive brachytherapy in locally advanced cervical cancer (LACC).
Methods And Materials: Patient-reported symptoms (European Organization for Research and Treatment of Cancer [EORTC]-C30/CX24) and physician-assessed morbidity (Common Terminology Criteria for Adverse Events [CTCAE], version 3.0) were assessed at baseline and regular timepoints during follow-up.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!